Systems biology approach for new target and biomarker identification.
The pharmaceutical industry is spending increasingly large amounts of money on the discovery and development of novel medicines, but this investment is not adequately paying off in an increased rate of newly approved drugs by the FDA. The post-genomic era has provided a wealth of novel approaches for generating large, high-dimensional genetic and transcriptomic data sets from large cohorts of preclinical species as well as normal and diseased individuals. This systems biology approach to understanding disease-related biology is revolutionizing our understanding of the cellular pathways and gene networks underlying the onset of disease, and the mechanisms of pharmacological treatments that ameliorate disease phenotypes. In this article, we review a number of approaches being used by pharmaceutical and biotechnology companies, e.g., high-throughput DNA genotyping, sequencing, and genome-wide gene expression profiling, to enable drug discovery and development through the identification of new drug targets and biomarkers of disease progression, drug pharmacodynamics, and predictive markers for selecting the patients most likely to respond to therapy.
Informatics and Analysis, Merck Research Laboratory, West Point, PA 19486, USA. I_ming_wang@merck.com
I-Ming
IM
Wang
David J
DJ
Stone
David
D
Nickle
Andrey
A
Loboda
Oscar
O
Puig
Christopher
C
Roberts
D000375:Aging; D000818:Animals; D015415:Biomarkers; D055808:Drug Discovery / Q000379:methods*; D053263:Gene Regulatory Networks; D005823:Genetics; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D049490:Systems Biology / Q000379:methods*
D015415:Biomarkers